Scholarlink

<p>Pathogenic MSTO1 mutations cause cerebellar ataxia and congenital myopathy, yet their molecular mechanisms remain poorly understood. This study identifies MSTO1 as a crucial regulator of mitochondrial genome integrity through direct interaction with RAD51. MSTO1 deficiency enhances RAD51 binding to mitochondrial DNA (mtDNA), disrupting mtDNA replication and causing mtDNA damage. This interaction, mediated by the conserved FxxA motif, specifically regulates RAD51’s mitochondrial activity without affecting its nuclear roles. Loss of MSTO1 impairs mitochondrial membrane potential, reduces mtDNA content, and increases susceptibility to oxidative stress. Furthermore, MSTO1 deficiency triggers BAX/BAK-dependent mtDNA leakage, activating the cGAS-STING pathway and driving inflammatory responses. Clinical bioinformatics further link low MSTO1 expression with immune activation in cancers. Our findings establish MSTO1 as a modulator of RAD51 activity within mitochondria, regulating mitochondrial stability and immune responses. This provides insights into MSTO1-related diseases and suggests MSTO1 as a potential target for activating anti-tumor immune responses in cancer cells.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MSTO1 modulates RAD51 activity to safeguard mitochondrial DNA integrity and control immune responses

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Kaiqi Cheng,
  • Zhanzhan Xu,
  • Jiansong Liu,
  • Yichen Pan,
  • Chen Nie,
  • Zuchao Mao,
  • Haodong Lin,
  • Yingyu Qin,
  • Shuqi Cao,
  • Xiaoman Li,
  • Weibin Wang,
  • Shiwei Li,
  • Jiadong Wang

摘要

Pathogenic MSTO1 mutations cause cerebellar ataxia and congenital myopathy, yet their molecular mechanisms remain poorly understood. This study identifies MSTO1 as a crucial regulator of mitochondrial genome integrity through direct interaction with RAD51. MSTO1 deficiency enhances RAD51 binding to mitochondrial DNA (mtDNA), disrupting mtDNA replication and causing mtDNA damage. This interaction, mediated by the conserved FxxA motif, specifically regulates RAD51’s mitochondrial activity without affecting its nuclear roles. Loss of MSTO1 impairs mitochondrial membrane potential, reduces mtDNA content, and increases susceptibility to oxidative stress. Furthermore, MSTO1 deficiency triggers BAX/BAK-dependent mtDNA leakage, activating the cGAS-STING pathway and driving inflammatory responses. Clinical bioinformatics further link low MSTO1 expression with immune activation in cancers. Our findings establish MSTO1 as a modulator of RAD51 activity within mitochondria, regulating mitochondrial stability and immune responses. This provides insights into MSTO1-related diseases and suggests MSTO1 as a potential target for activating anti-tumor immune responses in cancer cells.